FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891578442> ?p ?o ?g. }

• W2891578442 endingPage "10521" @default.
• W2891578442 startingPage "10521" @default.
• W2891578442 abstract "10521 Background: The effect of complete macroscopic excision (CME) of the primary tumour on event free survival (EFS) in high-risk neuroblastoma remains controversial. We therefore investigated the influence of CME in patients enrolled on the HR-NBL1/SIOPEN Trial and compared the effect in the pre immunotherapy era. Methods: Eligibility criteria were: inclusion in HR-NBL1/SIOPEN Trial between 2002-2015, stage 4 disease; completion of Rapid COJEC induction ± 2 courses of TVD; no progression/relapse/death; no prior attempt at resection and complete operation data. Intended therapy following operation comprised: HDT/SCT (BuMel or CEM, after 2011 BuMel), 21Gy radiotherapy to the primary site, 13-cis RA and after 2009 ch14.18/CHO antibody ± IL2 in addition. 1504 patients fulfilled these criteria; 737 were treated prior to ch14.18/CHO availability (2002-2009) and 767 in the immunotherapy era. Median observation time was 4.9 years (0.1-14 years). Results: CME was achieved in 77%, incomplete macroscopic excision (IME) in 21% and 2% were inoperable (0E). Surgical mortality was 0.46% (7/1504). Five year event-free survival (5y-EFS ± standard error) was 39%±2% with CME and 30%±3% with IME or 0E (p = 0.002). The cumulative incidence of local relapse (CILR) was 0.17±0.01 (CME); 0.31±0.03 (IME) and 0.42 ±0.10 (0E) (p < 0.001). 88% of patients received radiotherapy (78% CME; 21% IME and 1% 0E). 5y-EFS for patients with CME who received radiotherapy was 44±2%, but 31±6% without (reasons included very young age and very large primary tumours) (p = 0.013) and 35±3% with less than CME compared to 20±1% without radiotherapy (NS). CILR was 0.14±0.01 in patients with CME who received radiotherapy compared to 0.28±0.06 in patients who did not (p = 0.005). 5y-EFS was significantly higher (42±2%) for patients enrolled after 2009 compared to before (32±2%) (p = 0.000). 5-y EFS for patients after 2009 who achieved CME was 45±2% vs. 36±2% after IME and 26±13% after 0E respectively (p = 0.034); compared to 33±2% vs. 26±4% (IME) and 17±11% (0E) (p = 0.059) prior to 2009. Conclusions: In the immunotherapy era, CME in Stage 4 patients who received local radiotherapy resulted in improved 5-EFS. Clinical trial information: NCT01704716." @default.
• W2891578442 created "2018-09-27" @default.
• W2891578442 creator A5002553674 @default.
• W2891578442 creator A5007777254 @default.
• W2891578442 creator A5008197312 @default.
• W2891578442 creator A5009947836 @default.
• W2891578442 creator A5011042532 @default.
• W2891578442 creator A5011873942 @default.
• W2891578442 creator A5015184746 @default.
• W2891578442 creator A5018970052 @default.
• W2891578442 creator A5019321682 @default.
• W2891578442 creator A5020702311 @default.
• W2891578442 creator A5036969722 @default.
• W2891578442 creator A5040158837 @default.
• W2891578442 creator A5040708765 @default.
• W2891578442 creator A5041424600 @default.
• W2891578442 creator A5043581627 @default.
• W2891578442 creator A5046183097 @default.
• W2891578442 creator A5052706160 @default.
• W2891578442 creator A5073095613 @default.
• W2891578442 creator A5073205467 @default.
• W2891578442 creator A5079205425 @default.
• W2891578442 date "2018-05-20" @default.
• W2891578442 modified "2023-10-02" @default.
• W2891578442 title "The influence of surgical excision on survival in high-risk neuroblastoma revisited after introduction of ch14.18/CHO immunotherapy in the HR-NBL1/SIOPEN trial." @default.
• W2891578442 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.10521" @default.
• W2891578442 hasPublicationYear "2018" @default.
• W2891578442 type Work @default.
• W2891578442 sameAs 2891578442 @default.
• W2891578442 citedByCount "10" @default.
• W2891578442 countsByYear W28915784422018 @default.
• W2891578442 countsByYear W28915784422019 @default.
• W2891578442 countsByYear W28915784422020 @default.
• W2891578442 countsByYear W28915784422021 @default.
• W2891578442 crossrefType "journal-article" @default.
• W2891578442 hasAuthorship W2891578442A5002553674 @default.
• W2891578442 hasAuthorship W2891578442A5007777254 @default.
• W2891578442 hasAuthorship W2891578442A5008197312 @default.
• W2891578442 hasAuthorship W2891578442A5009947836 @default.
• W2891578442 hasAuthorship W2891578442A5011042532 @default.
• W2891578442 hasAuthorship W2891578442A5011873942 @default.
• W2891578442 hasAuthorship W2891578442A5015184746 @default.
• W2891578442 hasAuthorship W2891578442A5018970052 @default.
• W2891578442 hasAuthorship W2891578442A5019321682 @default.
• W2891578442 hasAuthorship W2891578442A5020702311 @default.
• W2891578442 hasAuthorship W2891578442A5036969722 @default.
• W2891578442 hasAuthorship W2891578442A5040158837 @default.
• W2891578442 hasAuthorship W2891578442A5040708765 @default.
• W2891578442 hasAuthorship W2891578442A5041424600 @default.
• W2891578442 hasAuthorship W2891578442A5043581627 @default.
• W2891578442 hasAuthorship W2891578442A5046183097 @default.
• W2891578442 hasAuthorship W2891578442A5052706160 @default.
• W2891578442 hasAuthorship W2891578442A5073095613 @default.
• W2891578442 hasAuthorship W2891578442A5073205467 @default.
• W2891578442 hasAuthorship W2891578442A5079205425 @default.
• W2891578442 hasConcept C120665830 @default.
• W2891578442 hasConcept C121332964 @default.
• W2891578442 hasConcept C121608353 @default.
• W2891578442 hasConcept C126322002 @default.
• W2891578442 hasConcept C141071460 @default.
• W2891578442 hasConcept C143998085 @default.
• W2891578442 hasConcept C146357865 @default.
• W2891578442 hasConcept C151730666 @default.
• W2891578442 hasConcept C2776715637 @default.
• W2891578442 hasConcept C2777701055 @default.
• W2891578442 hasConcept C2911091166 @default.
• W2891578442 hasConcept C509974204 @default.
• W2891578442 hasConcept C54355233 @default.
• W2891578442 hasConcept C61511704 @default.
• W2891578442 hasConcept C71924100 @default.
• W2891578442 hasConcept C81885089 @default.
• W2891578442 hasConcept C86803240 @default.
• W2891578442 hasConcept C88879693 @default.
• W2891578442 hasConceptScore W2891578442C120665830 @default.
• W2891578442 hasConceptScore W2891578442C121332964 @default.
• W2891578442 hasConceptScore W2891578442C121608353 @default.
• W2891578442 hasConceptScore W2891578442C126322002 @default.
• W2891578442 hasConceptScore W2891578442C141071460 @default.
• W2891578442 hasConceptScore W2891578442C143998085 @default.
• W2891578442 hasConceptScore W2891578442C146357865 @default.
• W2891578442 hasConceptScore W2891578442C151730666 @default.
• W2891578442 hasConceptScore W2891578442C2776715637 @default.
• W2891578442 hasConceptScore W2891578442C2777701055 @default.
• W2891578442 hasConceptScore W2891578442C2911091166 @default.
• W2891578442 hasConceptScore W2891578442C509974204 @default.
• W2891578442 hasConceptScore W2891578442C54355233 @default.
• W2891578442 hasConceptScore W2891578442C61511704 @default.
• W2891578442 hasConceptScore W2891578442C71924100 @default.
• W2891578442 hasConceptScore W2891578442C81885089 @default.
• W2891578442 hasConceptScore W2891578442C86803240 @default.
• W2891578442 hasConceptScore W2891578442C88879693 @default.
• W2891578442 hasIssue "15_suppl" @default.
• W2891578442 hasLocation W28915784421 @default.
• W2891578442 hasOpenAccess W2891578442 @default.
• W2891578442 hasPrimaryLocation W28915784421 @default.
• W2891578442 hasRelatedWork W2003938723 @default.
• W2891578442 hasRelatedWork W2047967234 @default.
• W2891578442 hasRelatedWork W2118496982 @default.

• next